ClinicalTrials.gg
RecruitingNCT05659160TRACK-LVO-2Updated Dec 1, 2023

Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2

An observational study in Stroke, Acute Ischemic, Endovascular Procedures and Large Vessel Occlusion, sponsored by Tianjin Huanhu Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Tianjin Huanhu Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.

Started
2021
the only one that year
Observational
6 of 12
6 open now
Primary completion
2028-12
later than 9 of 10 live
Registered
1st of 12
by date

Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is the only one that started in 2021, is one of 6 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 1st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, or all of them as a file.
02

Study summary

The objective of this study is to create a comprehensive, real-world, multi-center observational registry of consecutive patients admitted to hospitals with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO), who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).

Read the detailed description

The TRACK-LVO registry is an observational study conducted across multiple centers with the aim of improving the detection and treatment of large vessel occlusion (LVO) in acute ischemic stroke (AIS) patients. LVO is a major predictor of unfavorable outcomes in stroke patients, and the most effective imaging modalities for its detection remain a topic of debate.

To address this, the investigators will enroll consecutive AIS patients with LVO screened under different imaging modalities and compared the efficacy of endovascular therapy (EVT) and best medical management (BMM). The registry defines LVO as an occlusion of the intracranial ICA with or without the involvement of the terminal bifurcation, M1 and/or M2 segment of the MCA, A1 and/or A2 segment of the ACA, VA, BA, or P1 and/or P2 segment of the PCA. Patient information, including basic demographic profiles, imaging characteristics such as volume of ischemic core and occlusion site, and treatment-related complications will be collected for both EVT and BMM groups. For patients in the EVT group, detailed information on the EVT procedure and angiographic images will also be collected.

The study aims to identify the optimal imaging modalities for LVO detection and to compare the prognosis of AIS patients with LVO receiving EVT versus BMM. This academic, real-world, multi-center, observational registry will contribute valuable insights to improve the detection and treatment of LVO in AIS patients, ultimately improving patient outcomes and reducing the burden of stroke on public health and socio-economic development.

03

Conditions studied

  • Stroke, Acute Ischemic
  • Endovascular Procedures
  • Large Vessel Occlusion

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • Endovascular Therapy
  • Large Vessel Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All acute ischemic stroke patients with large vessel occlusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;
  2. Age ≥ 18;
  3. Ischemic stroke confirmed by head CT or MRI;
  4. Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1/P2);
  5. Patients receiving either endovascular therapy or best medical treatment;

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Endovascular therapy

    Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.

    Procedure: Endovascular Therapy

  • Best medical management

    Patients enrolled in this group received the best medical management.

Interventions

  • ProcedureEndovascular Therapy

    Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.

06

What researchers measure

Primary outcomes

  1. Modified ranking scale (mRS) at 90 days

    A 0-6 scale running from perfect health without symptoms to death.

    Time frame: 90 days

  2. Mortality within 90 days

    mortality of any causes.

    Time frame: 90 days

Secondary outcomes

  1. National Institutes of Health Stroke Scale (NIHSS) scores at 90 days

    The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

    Time frame: 90 days

  2. Occurrence of periprocedural complications

    Periprocedural complications include any intracranial hemorrhage, cerebral edema, brain herniation and pneumonia.

    Time frame: 14 days postoperatively

  3. ASPECT (Alberta Stroke Program Early CT score)

    ASPECTS is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke.

    Time frame: Day 0

  4. EuroQol five dimensions questionnaire (EQ-5D)

    The EQ-5D comprises five questions on mobility, self care, pain, usual activities, and psychological status with three possible answers for each item (1=no problem, 2=moderate problem, 3=severe problem). A summary index with a maximum score of 1 can be derived from these five dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions, where higher scores indicate more severe or frequent problems.

    Time frame: 1 year

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2028, 85 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 85 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Dec 21, 2022
StartActual
Nov 1, 2021
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05659160
Lead sponsor
Tianjin Huanhu Hospital
Responsible party
Ming Wei (Chief Physician, Tianjin Huanhu Hospital) — Principal investigator
First posted
Dec 21, 2022
Start date
Nov 1, 2021
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 1, 2023

Study contacts

Ming Wei, PhD
Contact
drweiming@163.com
13502182903

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion